Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2012

View Archived Issues

GSK develops new RAR-related orphan receptor-gamma modulators

Antigen Discovery's malaria research supported by new SBIR grant

Herbal extract mix efficacious in Alzheimer's disease model

Roche reports novel bradykinin B1 receptor antagonists

Boehringer Ingelheim Pharma patents new prostanoid DP2 receptor antagonists

New potential candidate cognition-enhancing drugs designed

Chinaberry fruit extract shows promise to treat Alzheimer's disease

Investigation yields novel candidate anticancer drugs

New candidate immunotherapies divulged by UCB

Novel complement activation-inhibiting products synthesized

Upsher-Smith Laboratories completes acquisition

Unigene and Nordic Bioscience select preliminary lead compound for type 2 diabetes

Novel silicon-containing compounds display antiallergic activity

Synergy Pharmaceuticals reaches enrollment target in plecanatide trial

Regulus Therapeutics forms microRNA alliance with AstraZeneca

Cortex Pharmaceuticals announces merger

Regulus and Biogen Idec establish biomarker collaboration

FDA clears phase I study of UMK-121

CRT licenses preclinical FAK inhibitor programs

Promising results reported for SNS01-T in multiple myeloma study

Safety monitoring board recommends continuation of PreSERVE-AMI trial

IND filed for APX-001

Lexicon Pharmaceuticals releases topline data on LX-2931 and LX-7101

Pluristem's PLX cells set to enter phase II study in India

FDA places partial clinical hold on Idenix program

Development collaboration begins for TGR-1202

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...